Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 125 for

Edit search filters
  1. A Study to Analyze CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

    Scottsdale/Phoenix, AZ

  2. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery

    Rochester, MN

  3. Phase I Trial of Sargramostim and Nivolumab for Metastatic Melanoma to the Lung

    Rochester, MN

  4. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

    Rochester, MN

  5. A Study of HFB200301 in Adult Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

    Rochester, MN

  7. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

    Rochester, MN

  8. A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma

    Rochester, MN, Jacksonville, FL

  10. A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

.

Mayo Clinic Footer